About Zhejiang Starry Pharmaceutical Company

The company was founded in 1997. The company is a large-scale enterprise with a complete range of domestic contrast agent generic products. Among them, the production capacity and output of iohexol raw materials rank among the highest in the country. On March 9, 2016, the company was listed on the Shanghai Stock Exchange. In November 2018, the company successfully acquired its domestic counterpart, Zhejiang Taizhou Hisense Pharmaceutical Co., Ltd., and entered the fast track of rapid development. The company is a high-tech enterprise specializing in R&D, production and sales of pharmaceutical specialty APIs. The company's main products are nonionic iodine contrast agent series drugs. As a high-tech enterprise, the company undertook a number of national and provincial research projects, successfully completed the acceptance of the results, and obtained a number of certificates. The “non-ionic X-CT contrast agent raw material - iohexol” project undertaken by the company obtained the “National Torch Program Project Certificate” issued by the Torch High-tech Industrial Development Center of the Ministry of Science and Technology of the People's Republic of China. Iohexol was also rated as a “Zhejiang High-tech Product” by the Zhejiang Science and Technology Department and as a “Taizhou Famous Brand Product” by the Taizhou Famous Brand Product Accreditation Committee. The “Synthesis Process Development and Industrialization of High-purity Nonionic X-CT Contrast Agent - Iohexol” project was awarded the “Second Prize for Science and Technology of Zhejiang Province” and the “First Prize for Science and Technology Progress in Taizhou” by the Zhejiang Provincial People's Government and the Taizhou Municipal People's Government respectively.